Compare AVPT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVPT | IMCR |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | United States | United Kingdom |
| Employees | 3443 | 524 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | 2016 |
| Metric | AVPT | IMCR |
|---|---|---|
| Price | $13.44 | $34.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | $16.64 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 2.1M | 456.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | $25.00 | $14.57 |
| Revenue Next Year | $19.63 | $8.21 |
| P/E Ratio | $1,348.94 | ★ $148.70 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $8.84 | $27.56 |
| 52 Week High | $16.77 | $40.71 |
| Indicator | AVPT | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 60.35 | 54.55 |
| Support Level | $11.88 | $30.48 |
| Resistance Level | $13.92 | $35.73 |
| Average True Range (ATR) | 0.50 | 1.24 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 74.82 | 66.77 |
AvePoint Inc is a provider of modern data protection, enabling organizations to secure, govern, and operationalize data at scale across cloud ecosystems. Customers rely on the AvePoint Confidence Platform to reduce risk, improve operational efficiency, and accelerate digital transformation as it adopt cloud collaboration and artificial intelligence (AI)-driven developed tools and workflows. Its products and services are sold throughout the world, through direct and indirect sales channels.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.